KalVista Pharmaceuticals (KALV) Non-Current Assets (2014 - 2025)
KalVista Pharmaceuticals recorded quarterly Non-Current Assets of $9.6 million in Q3 2025, up 5.83% quarter-over-quarter from $9.1 million in Q2 2025, and up 12.2% year-over-year from $8.6 million in Q3 2024.
KalVista Pharmaceuticals' Non-Current Assets history runs 12 years deep, the most recent figure standing at $9.6 million for Q3 2025.
- In Q3 2025, Non-Current Assets rose 12.2% year-over-year to $9.6 million; the TTM figure through Jul 2025 stood at $36.1 million (down 5.72% YoY), while the FY2025 annual figure was $9.1 million, down 6.53% from the prior year.
- Non-Current Assets came in at $9.6 million for Q3 2025 at KalVista Pharmaceuticals, up from $9.1 million in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $11.9 million in Q3 2022 to a low of $3.7 million in Q1 2021.
- A 5-year average of $9.6 million and a median of $9.7 million in 2024 frame the typical range for Non-Current Assets.
- Across the five-year window, Non-Current Assets soared 186.01% in 2022 and decreased 18.36% in 2024, its largest moves.
- KalVista Pharmaceuticals' Non-Current Assets stood at $9.3 million in 2021, then increased by 24.54% to $11.6 million in 2022, then fell by 12.78% to $10.1 million in 2023, then slipped by 12.82% to $8.8 million in 2024, then rose by 8.74% to $9.6 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $9.6 million, $9.1 million, and $8.8 million for Q3 2025, Q2 2025, and Q4 2024 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | 9.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | 9.61 Mn |
| Apr 30, 2025 | 9.08 Mn |
| Dec 31, 2024 | 8.84 Mn |
| Oct 31, 2024 | 8.56 Mn |
| Jul 31, 2024 | 8.56 Mn |
| Apr 30, 2024 | 9.71 Mn |
| Jan 31, 2024 | 9.87 Mn |
| Oct 31, 2023 | 10.14 Mn |
| Jul 31, 2023 | 10.49 Mn |
| Apr 30, 2023 | 10.88 Mn |
| Jan 31, 2023 | 11.34 Mn |
| Oct 31, 2022 | 11.62 Mn |
| Jul 31, 2022 | 11.91 Mn |
| Apr 30, 2022 | 10.23 Mn |
| Jan 31, 2022 | 10.59 Mn |
| Oct 31, 2021 | 9.33 Mn |
| Jul 31, 2021 | 9.35 Mn |
| Apr 30, 2021 | 7.75 Mn |
| Jan 31, 2021 | 3.70 Mn |
| Oct 31, 2020 | 3.37 Mn |
| Jul 31, 2020 | 3.68 Mn |
| Apr 30, 2020 | 3.83 Mn |
| Jan 31, 2020 | 3.93 Mn |
| Oct 31, 2019 | 4.17 Mn |
| Jul 31, 2019 | 4.17 Mn |
| Apr 30, 2019 | 2.59 Mn |
| Jan 31, 2019 | 2.46 Mn |
| Oct 31, 2018 | 2.49 Mn |
| Jul 31, 2018 | 2.43 Mn |
| Apr 30, 2018 | 2.01 Mn |
| Jan 31, 2018 | 947,000.00 |
| Oct 31, 2017 | 602,000.00 |
| Jul 31, 2017 | 592,000.00 |
| Apr 30, 2017 | 147,000.00 |
| Jan 31, 2017 | 97,000.00 |
| Mar 31, 2016 | 210,000.00 |
| Dec 31, 2015 | 1.85 Mn |
| Sep 30, 2015 | 630,000.00 |
| Jun 30, 2015 | 603,000.00 |
| Mar 31, 2015 | 3.40 Mn |
| Dec 31, 2014 | 2.06 Mn |